Great pharmalot interview with Marta Wosinska on drug shortages.

I often get asked why my drug shortage proposals focus so much on CMS. My answer: FDA has a too-important-to-fail problem, which means it cannot hold the red line on cGMPs. ed silverman captures it well in his story today.

I look forward to speaking with Jeremy Faust MD MS (ER physician) and Eleonora Teplinsky, MD, FASCO about what is driving chemotherapy drug shortages and how we can prevent future ones.

As you address #DrugShortages, please target #quality. Deficient quality underlies most drug shortages. Any added 💰 should aim to ⬆️ quality. Energy and Commerce Committee Energy & Commerce Democrats ⁦CathyMcMorrisRodgers⁩ ⁦Rep. Frank Pallone⁩ #StarRating #Accountability 👉tinyurl.com/5xbb9nrf

👉 Job alert for pharmacists! 👈 CMS is looking for a pharmacist to help implement Medicare negotiation provisions of the IRA. ⭐It's a remote position! ⭐ Applications due October 12. usajobs.gov/job/751701500

Do you enjoy working with health care claims data on policy-relevant topics? Come work at Brookings as a Senior Research Programmer, working closely with me, Matt Fiedler, Marta Wosinska, & Richard Frank. careers-brookings.icims.com/jobs/3292/seni…

This week, I was honored to testify at Senate Budget on administrative costs and at House Energy & Commerce on Medicare physician payment. A quick thread hitting the highlights of each testimony. Senate Budget: brookings.edu/articles/matth… House E&C: brookings.edu/articles/matth…

On 12/5, the US Senate Finance Committee will look into the economic root causes of drug shortages. I am eager to participate in the hearing, offering recommendations on how the Committee can guide and support CMS in tackling these shortages. finance.senate.gov/hearings/drug-…

We asked 6 The Brookings Institution economists about the issues they tracked in 2023 and what they'll be watching in 2024. Read what Dr. Chloe N. East she/her @chloeneast.bsky.social, Ben Harris, Sanjay Patnaik, Louise Sheiner, Tara E W, & Marta Wosinska had to say->-> brookings.edu/articles/major…

We asked 6 The Brookings Institution economists about the issues they tracked in 2023 and what they'll be watching in 2024. Read what Dr. Chloe N. East she/her @chloeneast.bsky.social, Ben Harris, Sanjay Patnaik, Louise Sheiner, Tara E W, & Marta Wosinska had to say->-> brookings.edu/articles/major…

"If we want resilience of our #supplychains, we'll have to pay for it," said ⁦Marta Wosinska⁩...⁦at The Brookings Institution⁩ "How we're going to pay for it is going to depend on the mechanisms through which we're going to build resilience." #DrugShortages axios.com/2024/01/05/ame…

The U.S. Pharmacopeia Medicine Supply Map shows why onshoring is not the solution to generic sterile injectable shortages. Instead, we need to realign hospital incentives, so they put more weight on reliability of supply.

How can U.S. policymakers effectively tackle drug shortages? Marta Wosinska presents a four-part test to evaluate potential policy solutions: brookings.edu/articles/drug-…

Shortages of amoxicillin, cancer drugs, and ADHD treatments have thrown the reliability of the US drug supply chain into question. In a new paper, Marta Wosinska lays out a four-part test for whether policies will strengthen the US drug supply chain. brookings.edu/articles/drug-…

Drug shortages bring disruptions in medical care and threaten patient harm. Yet "building reliability into supply chains does not come for free," Marta Wosinska writes. Read Marta's four-part test for cost-effective solutions to US drug shortages. brookings.edu/articles/drug-…

So excited our paper on the US generic drug market is out Thank you Heidi L. Williams & Timothy Taylor Marta Wosinska